GH Research price target raised to $40 from $33 at RBC Capital

RBC Capital raised the firm’s price target on GH Research (GHRS) to $40 from $33 and keeps an Outperform rating on the shares. Following the firm’s Psychedelics Symposium and discussions with the management, payers, and doctors, RBC is increasingly optimistic on GH’s long- term sales opportunity, with GH001, the analyst tells investors in a research note.